CLINICAL PIPELINE
Furthering therapies for the prevention and treatment of vector-borne diseases
Tafenoquine for multiple uses
With the success of tafenoquine for travel malaria, we are looking to expand the utility of tafenoquine for additional indications.1
In nonclinical and clinical studies, tafenoquine has shown promise against babesiosis by clearing persistent infections, overcoming resistance, and potentially providing lasting immunity.1-3
We are also evaluating the use of tafenoquine in canine piroplasmosis and beyond.4
= Completed
= Next Phase
*Non-notification letter received from NDIN submitted March 11, 2026. Resubmission pending outcome of FDA meetings and completion of to-be-determined gap-filling and safety studies.
FDA=US Food and Drug Administration; IND=Investigational New Drug; NDIN=New Dietary Ingredient Notification.
References: 1. Liu M, Ji S, Kondoh D, et al. Tafenoquine is a promising drug candidate for the treatment of babesiosis. Antimicrob Agents Chemother. 2021;65(7):e0020421. doi:10.1128/AAC.00204-21 2. Vydyam P, Pal AC, Renard I, et al. Tafenoquine–atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human babesiosis. J Infect Dis. 2024;229(1):161-172. doi:10.1093/infdis/jiad315 3. Krause PJ, Rogers R, Shah MK, et al. Tafenoquine for relapsing babesiosis: a case series. Clin Infect Dis. 2024;79(1):130-137. doi:10.1093/cid/ciae238 4. Iguchi A, Mochiduki Y, Akiyama H, et al. Efficacy of tafenoquine in dogs naturally infected with Babesia gibsoni. J Vet Med Sci. 2025;87(5): 532-535. doi:10.1292/jvms.24-0443